Renaissance Capital logo

CollPlant, a micro-cap regenerative tissue biotech, files for a $25 million IPO

October 21, 2016
CLGN

CollPlant, a clinical-stage biotech focused on regenerative medicine for tissue repair, filed on Friday with the SEC to raise up to $25 million in an initial public offering.

The Ness-Ziona, Israel-based company was founded in 2004. It plans to list on the Nasdaq under the symbol CLGN. Ladenburg Thalmann & Co. is the sole bookrunner on the deal. No pricing terms were disclosed.